Makowski lab graduate student Mehdi Chaib has published “PKC agonism restricts innate immune suppression, promotes antigen cross-presentation and synergizes with agonistic CD40 antibody therapy to activate CD8 + T cells in breast cancer” in Cancer Letters (here). Congratulations Mehdi!
Highlights:
-
•PKC agonism suppresses murine breast cancer tumor growth in vivo.
-
•PKC agonism impairs MDSC expansion, trafficking, and suppressive capacity and favors cDC1 expansion.
-
•PKC agonism induces M-MDSC differentiation to cross-presenting DC-like cells via activation of the p38 MAPK pathway.
-
•Combination of PKC agonism and agonistic CD40 synergistically promotes activation of intratumoral CD8+ T cells and tissue-resident memory CD8+ T cells (Trm) in vivo.
-
.